Alzheimer's Drug Shows Promise in Fighting Cancer ( cer Institute-designated comprehensive ...)

Alzheimer's Drug Shows Promise in Fighting Cancer

cer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. John C. Ruckdeschel, M.D. is the Institute's president and CEO.

Barbara Ann Karmanos Cancer Institute

CONTACT: Courtney McCrimmon, +1-412-225-6899, or Linda Remington,+1-313-576-8614, both of Barbara Ann Karmanos Cancer Institute

Web site: http://www.karmanos.org/

Page: 1 2
Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. At the 2007 Alzheimers Association International Conference on the Prevention of Dementia - Neurochems U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)
5. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
6. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
7. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
8. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
9. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
10. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
11. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease

Post Your Comments:

( cer Institute-designated comprehensive ...)Alzheimer's Drug Shows Promise in Fighting Cancer,Health